Scleroderma Treatment With Celution Processed ADRCs Registry

NCT02328625 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-03-17

No results posted yet for this study

Summary

This registry study will assess the safety and performance of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand scleroderma.

Conditions

  • Scleroderma

Sponsors & Collaborators

  • Cytori Therapeutics

    lead INDUSTRY

Principal Investigators

  • Steven Kesten · Cytori Therapeutics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-08-31
Completion
2017-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02328625 on ClinicalTrials.gov